StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO)

Analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued on Monday. The firm set a “hold” rating on the medical research company’s stock.

CTSO has been the subject of a number of other research reports. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a report on Monday, November 11th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Trading Down 3.8 %

Shares of Cytosorbents stock opened at $1.01 on Monday. The firm has a market capitalization of $55.23 million, a PE ratio of -2.81 and a beta of 0.78. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The firm’s 50-day moving average price is $1.05 and its 200 day moving average price is $1.05. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Institutional Trading of Cytosorbents

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in shares of Cytosorbents during the 4th quarter worth approximately $30,000. Northern Trust Corp increased its holdings in shares of Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after buying an additional 16,701 shares during the last quarter. Avenir Corp increased its holdings in shares of Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock worth $2,815,000 after buying an additional 118,387 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents during the 4th quarter worth approximately $99,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after buying an additional 8,400 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.